Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RGNX

Regenxbio Inc

Dec 11 • 04:00PM ET

9.30

Dollar change -0.46
Percentage change -4.71	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BMRN NTLA EDIT QURE SRPT ADVM BLUE VYGR CLLS

| Held by: IJR IWM VTI XBI VXF VB IWN SPSM IBB VBK

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.03	Insider Own	9.47%	Shs Outstand	49.53M	Perf Week	1.53%
Market Cap	460.77M	Forward P/E	-	EPS next Y	-0.72	Insider Trans	-1.89%	Shs Float	44.85M	Perf Month	-19.55%
Income	-238.81M	PEG	-	EPS next Q	-1.12	Inst Own	90.27%	Short Float	11.73%	Perf Quarter	-23.65%
Sales	84.33M	P/S	5.46	EPS this Y	21.64%	Inst Trans	0.01%	Short Ratio	6.80	Perf Half Y	-29.28%
Book/sh	6.09	P/B	1.53	EPS next Y	84.78%	ROA	-41.43%	Short Interest	5.26M	Perf Year	-52.04%
Cash/sh	5.16	P/C	1.80	EPS next 5Y	13.60%	ROE	-71.87%	52W Range	8.44 - 28.80	Perf YTD	-48.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-57.85%	52W High	-67.71%	Beta	1.24
Dividend TTM	-	Quick Ratio	3.05	Sales past 5Y	72.63%	Gross Margin	34.76%	52W Low	10.19%	ATR (14)	0.83
Dividend Ex-Date	-	Current Ratio	3.05	EPS Y/Y TTM	15.84%	Oper. Margin	-289.09%	RSI (14)	45.93	Volatility	10.45% 9.19%
Employees	344	Debt/Eq	0.48	Sales Y/Y TTM	-15.14%	Profit Margin	-283.19%	Recom	1.27	Target Price	35.73
Option/Short	Yes / Yes	LT Debt/Eq	0.37	EPS Q/Q	16.66%	Payout	-	Rel Volume	1.21	Prev Close	9.76
Sales Surprise	2.39%	EPS Surprise	-4.25%	Sales Q/Q	-16.31%	Earnings	Nov 06 AMC	Avg Volume	773.53K	Price	9.30
SMA20	-4.43%	SMA50	-4.88%	SMA200	-32.21%	Trades		Volume	934,791	Change	-4.71%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-24	Resumed	Morgan Stanley	Overweight	$22
Oct-10-24	Resumed	Raymond James	Outperform	$18
Jun-07-24	Initiated	Goldman	Buy	$38
Mar-11-24	Initiated	H.C. Wainwright	Buy	$36
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$20 → $35
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Feb-21-24	Resumed	Raymond James	Outperform	$45
Nov-01-23	Initiated	Stifel	Buy	$35
Jun-02-23	Initiated	Robert W. Baird	Outperform	$42
Jun-23-22	Initiated	Berenberg	Buy	$61
Dec-15-21	Initiated	Wedbush	Neutral	$29
Oct-19-21	Resumed	Morgan Stanley	Overweight	$62 → $50
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy	$60
Dec-16-20	Initiated	UBS	Buy	$57
Jun-25-20	Resumed	BofA/Merrill	Buy	$9
Jun-25-20	Resumed	BofA/Merrill	Buy	$60
May-13-20	Initiated	RBC Capital Mkts	Sector Perform	$42
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform	$38 → $37
Jun-18-19	Reiterated	Chardan Capital Markets	Buy	$145 → $150
Jun-14-19	Resumed	Raymond James	Outperform

Show Previous Ratings

Dec-06-24 06:29PM	Apollo Global Management and Workday Set to Join SandP 500; Others to Join SandP MidCap 400 and SandP SmallCap 600 (PR Newswire) +9.61% +6.16%
06:29PM	Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-19-24 12:32PM	Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy (Pharmaceutical Technology) -5.81%
Nov-18-24 07:05AM	REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA (PR Newswire) +5.40%
05:23AM	FDA endorses speedy approval path for Regenxbio Duchenne gene therapy (BioPharma Dive)
07:05AM	Loading…
Nov-14-24 07:05AM	REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE Trial of RGX-202 (PR Newswire)
Nov-07-24 02:22AM	Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... (GuruFocus.com) +18.66%
Nov-06-24 06:00PM	Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.72%
05:02PM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates (PR Newswire)
Nov-05-24 07:59AM	Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Oct-30-24 07:05AM	REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
Oct-21-24 07:05AM	REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 (PR Newswire) -6.58%
Oct-18-24 07:05AM	REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (PR Newswire)
03:04PM	Loading…
Oct-17-24 03:04PM	JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc (GuruFocus.com)
Sep-23-24 04:05PM	REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference (PR Newswire)
Sep-17-24 07:05AM	REGENXBIO Appoints Mitchell Chan as Chief Financial Officer (PR Newswire)
Sep-04-24 09:15AM	New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth (GlobeNewswire)
Sep-03-24 01:33PM	RegenxBio touts positive data for rare disease drug RGX-121 (Pharmaceutical Technology) -7.20%
08:04AM	REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect (PR Newswire)
Aug-29-24 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-27-24 07:05AM	REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (PR Newswire)
Aug-08-24 07:05AM	REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (PR Newswire)
06:00AM	7 Biotech Stocks to Buy for Their Game-Changing Potential (InvestorPlace)
Aug-06-24 09:55AM	Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet (Zacks)
Aug-01-24 05:45PM	Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.60%
04:46PM	Regenxbio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
07:03AM	REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire)
07:01PM	Loading…
Jul-30-24 07:01PM	Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX) (GuruFocus.com)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 07:05AM	REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire) +5.50%
Jul-12-24 09:59AM	Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains? (Zacks)
Jun-27-24 10:05AM	Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey) -6.57%
Jun-25-24 04:32AM	Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace) +6.41%
07:05AM	REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger Patients (PR Newswire)
Jun-21-24 04:28PM	Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy (Investor's Business Daily)
06:40AM	Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy (Investor's Business Daily)
Jun-18-24 07:05AM	REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II (PR Newswire)
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-12-24 08:00AM	Regenxbio CEO to step down after 15 years (BioPharma Dive)
07:05AM	REGENXBIO Announces Leadership Transition (PR Newswire)
Jun-05-24 07:05AM	REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
May-15-24 11:38AM	HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating (MT Newswires)
May-10-24 02:30PM	Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts (GuruFocus.com)
07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
May-09-24 03:53PM	REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.94%
11:11AM	UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating (MT Newswires)
07:11AM	Q1 2024 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
03:46AM	Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ... (GuruFocus.com)
May-08-24 09:56PM	RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:40PM	Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:44PM	Regenxbio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
May-01-24 07:05AM	REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire) +5.54%
Apr-24-24 07:05AM	REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (PR Newswire)
Mar-28-24 01:09PM	REGENXBIO Sees Positive Results For Macular Degeneration Therapy (Exec Edge) -5.00%
07:05AM	REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD (PR Newswire)
Mar-27-24 04:05PM	REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days (PR Newswire)
Mar-18-24 07:00PM	Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares (GuruFocus.com)
Mar-13-24 08:00AM	Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? (Motley Fool)
Mar-11-24 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-08-24 01:29AM	Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares (GuruFocus.com)
Mar-06-24 11:20PM	REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants (PR Newswire)
04:10PM	REGENXBIO Announces Proposed Public Offering of Common Stock (PR Newswire)
11:33AM	REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study (Zacks)
03:01AM	Regenxbio data suggest niche in Duchenne gene therapy (BioPharma Dive)
Mar-05-24 07:05AM	REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL (PR Newswire) +15.22%
Feb-29-24 04:57PM	REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE Trial (PR Newswire) -12.36% +21.50%
Feb-28-24 11:05AM	Q4 2023 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
09:36AM	REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 05:35PM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +9.16%
04:41PM	Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights (GuruFocus.com)
04:32PM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-21-24 07:05AM	REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-17-24 12:07AM	Regenxbio Inc President and CEO Kenneth Mills Sells 15,000 Shares (GuruFocus.com)
Feb-08-24 09:36AM	REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up (Zacks) +11.81%
04:50AM	Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength? (Zacks)
Feb-07-24 11:40AM	REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint (PR Newswire) +11.65%
07:05AM	REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE Trial (PR Newswire)
Jan-31-24 07:05AM	REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 (PR Newswire)
Jan-18-24 09:01PM	Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares (GuruFocus.com)
Jan-16-24 02:47PM	REGENXBIO Announces Positive Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery (PR Newswire)
Jan-10-24 07:05AM	REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting (PR Newswire)
Jan-09-24 06:20PM	Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX) (Zacks)
Jan-08-24 07:05AM	U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit (PR Newswire) -12.22%
Dec-22-23 09:01AM	Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares (GuruFocus.com)
Nov-29-23 07:05AM	REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE Trial (PR Newswire)
Nov-16-23 09:55AM	Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to Trade (Zacks)
Nov-09-23 04:46PM	REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.13%
06:37AM	'Difficult, but necessary, steps': SQZ lays off 80% of staff, Regenxbio cuts 15% (FierceBiotech.com)
Nov-08-23 04:42PM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results (PR Newswire)
Nov-07-23 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-03-23 06:53PM	REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery (PR Newswire) +8.03%
Nov-01-23 07:05AM	REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire) +10.09%

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KARABELAS ARGERIS N	Director	Oct 01 '24	Option Exercise	3.76	10,000	37,600	21,286	Oct 02 04:31 PM
KARABELAS ARGERIS N	Director	Oct 01 '24	Sale	10.11	10,000	101,052	11,286	Oct 02 04:31 PM
KARABELAS ARGERIS N	Director	Sep 03 '24	Option Exercise	3.76	10,000	37,600	21,286	Sep 04 08:20 PM
KARABELAS ARGERIS N	Director	Sep 03 '24	Sale	11.56	10,000	115,588	11,286	Sep 04 08:20 PM
Mills Kenneth T.	Director	Aug 08 '24	Option Exercise	0.85	36,316	30,869	444,351	Aug 12 04:58 PM
KARABELAS ARGERIS N	Director	Aug 01 '24	Option Exercise	3.85	10,100	38,874	21,386	Aug 05 06:39 PM
KARABELAS ARGERIS N	Director	Aug 01 '24	Sale	13.51	10,100	136,454	11,286	Aug 05 06:39 PM
Simpson Curran	Chief Executive Officer	Aug 01 '24	Sale	15.00	100	1,500	170,037	Aug 05 06:39 PM
ARGERIS N KARABELAS	Director	Aug 01 '24	Proposed Sale	14.25	31,000	441,750		Aug 01 04:34 PM
KARABELAS ARGERIS N	Director	Jul 29 '24	Option Exercise	12.74	11,000	140,140	22,286	Jul 30 05:01 PM
KARABELAS ARGERIS N	Director	Jul 29 '24	Sale	15.04	11,000	165,495	11,286	Jul 30 05:01 PM
Simpson Curran	Chief Executive Officer	Jul 29 '24	Sale	15.04	9,648	145,106	170,137	Jul 30 05:01 PM
CURRAN M SIMPSON	Director	Jul 29 '24	Proposed Sale	14.33	25,106	359,769		Jul 29 04:13 PM
Mills Kenneth T.	Director	Jul 25 '24	Option Exercise	3.76	15,369	57,787	423,404	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 24 '24	Option Exercise	3.76	12,221	45,951	420,256	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 25 '24	Sale	13.96	15,369	214,501	408,035	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 24 '24	Sale	13.78	12,221	168,433	408,035	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 17 '24	Option Exercise	3.76	2,210	8,310	410,245	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 16 '24	Option Exercise	3.76	200	752	408,235	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 17 '24	Sale	13.77	2,210	30,440	408,035	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 16 '24	Sale	13.76	200	2,752	408,035	Jul 18 05:05 PM
KARABELAS ARGERIS N	Director	Jul 01 '24	Option Exercise	3.76	10,000	37,600	21,286	Jul 03 07:55 AM
KARABELAS ARGERIS N	Director	Jul 01 '24	Sale	11.27	10,000	112,691	11,286	Jul 03 07:55 AM
Mills Kenneth T.	President and CEO	May 14 '24	Option Exercise	3.76	15,000	56,400	423,035	May 16 05:06 PM
Mills Kenneth T.	President and CEO	May 14 '24	Sale	15.81	15,000	237,222	408,035	May 16 05:06 PM
Mills Kenneth T.	President and CEO	Apr 15 '24	Option Exercise	3.76	15,000	56,400	423,035	Apr 17 05:05 PM
Mills Kenneth T.	President and CEO	Apr 15 '24	Sale	18.19	15,000	272,871	408,035	Apr 17 05:05 PM
Vasista Vittal	Chief Financial Officer	Mar 19 '24	Option Exercise	3.76	20,041	75,354	246,534	Mar 21 05:20 PM
Mills Kenneth T.	President and CEO	Mar 14 '24	Option Exercise	3.76	15,000	56,400	423,035	Mar 18 05:03 PM
Mills Kenneth T.	President and CEO	Mar 14 '24	Sale	21.86	15,000	327,942	408,035	Mar 18 05:03 PM
PAKOLA STEVE	Chief Medical Officer	Mar 05 '24	Option Exercise	22.25	12,878	286,536	120,070	Mar 07 06:05 PM
PAKOLA STEVE	Chief Medical Officer	Mar 05 '24	Sale	28.36	12,878	365,220	107,192	Mar 07 06:05 PM
Mills Kenneth T.	President and CEO	Feb 14 '24	Option Exercise	3.76	15,000	56,400	423,035	Feb 16 06:28 PM
Mills Kenneth T.	President and CEO	Feb 14 '24	Sale	16.76	15,000	251,349	408,035	Feb 16 06:28 PM
Mills Kenneth T.	President and CEO	Jan 16 '24	Option Exercise	3.76	45,000	169,200	453,035	Jan 18 06:39 PM
Mills Kenneth T.	President and CEO	Jan 16 '24	Sale	15.18	45,000	682,992	408,035	Jan 18 06:39 PM
PAKOLA STEVE	Chief Medical Officer	Jan 03 '24	Sale	17.39	17,237	299,789	107,192	Jan 04 04:23 PM
Mills Kenneth T.	President and CEO	Dec 19 '23	Option Exercise	3.66	45,000	164,835	400,289	Dec 21 01:38 PM
Mills Kenneth T.	President and CEO	Dec 19 '23	Sale	19.68	45,000	885,825	355,289	Dec 21 01:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNX

Regenxbio Inc

Upgrade your FINVIZ experience